Krystal Biotech: When Gene Therapy Becomes Routine

Krystal Biotech differentiates itself from the competition with its approved drug Vyjuvek, as the necessary weekly application transforms the classic "One-and-Done" model of gene therapy into a steady, recurring revenue source. The crucial competitive advantage is the proprietary STAR-D technology, which, unlike conventional methods, does not trigger immune resistance and therefore enables a persistently repeatable dosage as the first platform. The future price potential largely depends on whether the proven technology can be successfully...